Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Determine mutations that arise as a result of gene correction of a Cystic Fibrosis patient

PROVIDER: PRJNA291406 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR2136532.fastq.gz	Fastqsanger.gz
	SRR2136532_1.fastq.gz	Fastqsanger.gz
	SRR2136532_2.fastq.gz	Fastqsanger.gz
	SRR2136533.fastq.gz	Fastqsanger.gz
	SRR2136533_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Homo sapiens

Project description:Targeted Correction of CFTR Gene in Cystic Fibrosis iPS Exome Seq

| PRJNA174513 | ENA

Distinct proteostasis states drive pharmacologic chaperone susceptibility for Cystic Fibrosis Transmembrane Conductance Regulator misfolding mutants

Project description:Pharmacological chaperones represent a class of therapeutic compounds for treating protein misfolding diseases. One of the most prominent examples is the FDA-approved pharmacological chaperone lumacaftor (VX-809), which has transformed cystic fibrosis (CF) therapy. CF is a fatal disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). VX-809 corrects folding of F508del CFTR, the most common patient mutation, yet F508del exhibits only mild VX-809 response. In contrast, rarer mutations P67L and L206W are hyper-responsive to VX-809, while G85E is non-responsive. Despite the clinical success of VX-809, the mechanistic origin for the distinct susceptibility of mutants remains unclear. Here, we use interactomics to characterize the impact of VX-809 on proteostasis interactions of P67L and L206W and compare these to F508del and G85E. We determine hyper-responsive mutations P67L and L206W exhibit decreased interactions with proteasomal, and autophagy degradation machinery compared to F508del and G85E. We then show inhibiting the proteasome attenuates P67L and L206W VX-809 response. Our data suggests a previously unidentified but required role for protein degradation in VX-809 correction. Furthermore, we present an approach for identifying proteostasis characteristics of mutant-specific therapeutic response to pharmacological chaperones.

2022-05-04 | PXD032836 | Pride

Homo sapiens

Project description:Targeted gene correction of LMNA mutations in patient-specific iPSCs

| PRJNA138755 | ENA

Homo sapiens immortalized MSCs: 3A6

Project description:Gene expression profiling of immortalized human mesenchymal stem cells with hTERT/E6/E7 transfected MSCs. hTERT may change gene expression in MSCs. Goal was to determine the gene expressions of immortalized MSCs.

2010-09-25 | GSE24338 | GEO

Homo sapiens MSCs: Normoxia vs. Hypoxia

Project description:Transcriptional profiling of human mesenchymal stem cells comparing normoxic MSCs cells with hypoxic MSCs cells. Hypoxia may inhibit senescence of MSCs during expansion. Goal was to determine the effects of hypoxia on global MSCs gene expression.

2011-02-19 | GSE20463 | GEO

Homo sapiens

Project description:Allele-Preferred Targeted Correction of CFTR Gene in Cystic Fibrosis Induced Pluripotent Stem Cells

| PRJNA174436 | ENA

Homo sapiens

Project description:Human Cystic Fibrosis

| PRJNA91595 | ENA

Homo sapiens immortalized MSCs: 3A6

2010-09-25 | E-GEOD-24338 | biostudies-arrayexpress

Homo sapiens immortalized MSCs: KP vs. 3A6

Project description:Gene methylation profiling of immortalized human mesenchymal stem cells comparing HPV E6/E7-transfected MSCs cells with human telomerase reverse transcriptase (hTERT)- and HPV E6/E7-transfected MSCs. hTERT may increase gene methylation in MSCs. Goal was to determine the effects of different transfected genes on global gene methylation in MSCs.

2011-08-25 | GSE23936 | GEO

Homo sapiens

Project description:Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing.

| PRJNA551109 | ENA